In critical patients with severe COVID-19, pharmacologic inhibition of e.g. the CCR1 and/or CCR5 (2, 48) or the CXCL10:CXCR3 and the CXCL16:CXCR6 pathways (49, 50), respectively, were suggested to suppress hyperinflammation. The gene discussed is CXCL16; the disease is COVID-19.